Novartis AG (SWX:NOVN)
Switzerland · Delayed Price · Currency is CHF | Market Cap | 246.29B +23.4% |
| Revenue (ttm) | 45.81B +2.7% |
| Net Income | 10.31B -6.6% |
| EPS | 5.34 -3.4% |
| Shares Out | 1.90B |
| PE Ratio | 24.24 |
| Forward PE | 17.63 |
| Dividend | 3.70 (2.82%) |
| Ex-Dividend Date | Mar 10, 2026 |
| Volume | 3,077,526 |
| Open | 124.64 |
| Previous Close | 129.58 |
| Day's Range | 124.60 - 127.22 |
| 52-Week Range | 96.03 - 132.68 |
| Beta | 0.49 |
| Analysts | Hold |
| Price Target | 125.67 (+0.17%) |
| Earnings Date | Oct 27, 2026 |
About Novartis AG
Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6 (CDK4/6); Promacta/Revolade to treat immune thrombocy... [Read more]
Financial Performance
In 2025, Novartis AG's revenue was $56.67 billion, an increase of 9.57% compared to the previous year's $51.72 billion. Earnings were $13.98 billion, an increase of 17.11%.
Financial numbers in USD Financial StatementsAnalyst Summary
According to 22 analysts, the average rating for NOVN stock is "Hold." The 12-month stock price target is CHF 125.67, which is an increase of 0.17% from the latest price.
News
Citi says Novartis news increases likelihood Crispr prioritizes next-gen CTX321
After Novartis (NVS) reported that pelacarsen’s Phase 3 HORIZON study failed to demonstrate a statistically significant reduction in major adverse cardiovascular events despite lowering Lp(a), Citi be...
Citi sees limited immediate downside for Ionis after pelacarsen failure
After Ionis’ (IONS) partner Novartis (NVS) disclosed that the pelacarsen Phase 3 Lp(a)HORIZON study failed to meet its primary endpoint of cardiovascular risk reduction, Citi analyst Eric Joseph antic...
Novartis pelacarsen miss ‘not great on the margin for’ Amgen, says UBS
After Novartis (NVS) announced pelacarsen missed its primary endpoint of reducing cardiovascular events in the Phase 3 HORIZON study, UBS called the news “not great on the margin for” Amgen…
Novartis Just Lost a Potential $6 Billion Drug Opportunity
Novartis Just Lost a Potential $6 Billion Drug Opportunity
BofA sees low single-digit percentage downside for Novartis on pelacarsen miss
After Novartis (NVS) announced pelacarsen missed its primary endpoint of reducing cardiovascular events in the Phase 3 HORIZON study, BofA sees low single-digit percentage net present value downside d...
Novartis Shares Fall After Heart Drug Misses Target in Late-Stage Trial
The company said the late-stage study for its pelacarsen drug missed its primary objective of reducing the risk of cardiovascular events like death, heart attack and stroke compared with placebo.
Novartis shares down as failed cholesterol drug study increases pipeline pressure
Shares of Novartis fell 3.3% on Monday morning after its cholesterol drug failed in a closely watched study, casting fresh doubt on the therapeutic approach and raising the stakes for the Swiss dr...
A Novartis Heart Drug Trial Stumbles. Can a Rare-Disease Treatment Lift Shares?
In a consequential week for Novartis, the Swiss drug maker released results for two of three trials that Wall Street has watched for in the second half of the year.
Novartis' Pelacarsen Fails To Meet Primary Endpoint In Phase III Lp(a)HORIZON Trial
(RTTNews) - Novartis AG (NVS), a pharmaceutical company, on Friday announced that its phase III Lp(a)HORIZON trial of pelacarsen, an investigational cardiovascular therapy, failed to meet the primary ...
A highly anticipated cholesterol drug from Novartis failed to reduce the risk of severe cardiovascular outcomes in a Phase 3 study
The Phase 3 study found a drug didn't reduce the risk of cardiovascular events like heart attacks and strokes.
Novartis Says Pelacarsen Heart Disease Drug Missed Primary Endpoint
The company's shares declined in after-hours trading after the drug failed to reduce the risk of cardiovascular events in a Phase 3 study.
Novartis, Ionis Tumble On Surprise Flop For Heart Drug
Novartis said late Friday its Ionis-partnered Lp(a) blocker failed in testing. The results sent Novartis and Ionis stocks tumbling.
Ionis, Novartis' key experimental heart drug fails in late-stage trial
Ionis Pharmaceuticals and partner Novartis' experimental drug to lower high levels of a cholesterol-carrying particle in heart patients failed in a late-stage trial, the companies said on Friday.
Novartis announces Phase 3 pelacarsen study did not meet primary endpoint
Ionis Pharmaceuticals (IONS) partner Novartis (NVS) announced that the pelacarsen Phase 3 Lp(a)HORIZON study, a pioneering cardiovascular outcomes trial, did not meet its primary endpoint of reducing ...
Weekly Buzz: IONS, MIST, BIIB, AZN Win Nods; TCRX, NVS Cut Jobs; OVID, VIR Data; REGN, PASG Deals
(RTTNews) - This week's biotech roundup saw a flurry of FDA and EU approvals across neurology, oncology, cardiology, and rare diseases, alongside new partnerships, trial readouts, and restructuring mo...
Drugmakers quietly halted autoimmune drug trials because of deaths or problematic side effects, raising questions about disclosure around experimental research
Trial freezes by Novartis and Bristol Myers have triggered a race to understand why a promising autoimmune treatment turned risky.
Novartis Rises as $3.22 Billion Deal Targets Faster Drug Delivery
Novartis Rises as $3.22 Billion Deal Targets Faster Drug Delivery
Novartis Signs Up To $3.2B Hybrozyme Deal With Alteogen
(RTTNews) - Alteogen Inc. (196170.KQ), a South Korea-based biopharmaceutical company specializing in platform technologies, announced it has entered into an option and license agreement with Novartis ...
Novartis could cut about 130 jobs in Basel site relocation
Novartis could cut about 130 jobs in Switzerland as it relocates laboratory activities and shuts down some production in Basel, the Swiss drugmaker said on Wednesday.
Novartis signs deal worth up to $3.2 billion for Alteogen's drug delivery technology
South Korea's Alteogen said on Wednesday it has signed a deal with Novartis worth up to $3.22 billion, giving the Swiss drugmaker access to its technology to make injectable versions of intravenous dr...
A Look at Novartis AG (NVS) After 6.0% Gain -- GF Value $130.84 vs Price $161.25
A Look at Novartis AG (NVS) After 6.0% Gain -- GF Value $130.84 vs Price $161.25
Novartis Jumps 6% as MS Drug Meets Goals in Two Phase 3 Trials
Novartis Jumps 6% as MS Drug Meets Goals in Two Phase 3 Trials
H.C. Wainwright says Novartis success in RMS trials does not impact TG’s Briumvi
After Novartis (NVS) announced topline data from the REMODEL-1/-2 trials of remibrutinib in relapsing multiple sclerosis, H.C. Wainwright analyst Emily Bodnar believes that remibrutinib will be favore...
Novartis Reported Encouraging Trial Data for a Multiple Sclerosis Drug. The Stock Is Jumping
Promising results from a recent clinical trial are boosting Novartis shares this morning.
Novartis Stock (NVS) Pops as Multiple Sclerosis Drug Shows Positive Results in Late-Stage Trials
Novartis ($NVS) stock rose about 6% at the time of writing on Tuesday, after the Swiss drugmaker reported positive results from two late-stage trials of remibrutinib in relapsing multiple sclerosis.